Axogen Inc vs Raytheon Technologies Corp — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Raytheon Technologies Corp trades at $193.9 (market cap $260.44B). The key difference: Raytheon Technologies Corp is far larger — about 126.4× Axogen Inc's market cap, and Raytheon Technologies Corp pays a 1.51% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | RTX | |
|---|---|---|
Market Cap | $2.06B | $260.44B |
Sector | Technology | Industrials |
52-Week High | $46.19 | $212.16 |
52-Week Low | $11.28 | $148.68 |
Enterprise Value | $1.98B | $292.55B |
Dividend Yield | — | 1.51% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
RTX trades at $193.39, down 1.3% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding expectations of $1.51. Revenue grew to $88.60 billion in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award announced June 3, 2026, underscore its defense sector strength.
Outlook remains positive given earnings momentum and defense budget tailwinds, but valuation at a P/E of 36.85 poses a risk if growth slows. Analyst consensus price target of $213.00 suggests 10% upside, with no sell ratings among 26 coverage firms. Key risks include execution on production targets and geopolitical shifts affecting defense spending.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →